The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management

From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management

December 2, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Aggarwal

Dr. Rohit Aggarwal

ACR Convergence 2021—Idiopathic inflammatory myopathies (IIM) are heterogeneous, systemic diseases with muscle and/or skin as the primary targets, and diagnosing and treating these conditions correctly can be a major challenge for many rheumatologists. During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, professor of medicine, rheumatology and clinical immunology and co-director of the University of Pittsburgh Medical Center Myositis Center, provided an overview of this important topic.

You Might Also Like
  • New Approaches to Inflammatory Myopathy
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed
Also By This Author
  • The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Diagnostic Criteria

Many rheumatologists are familiar with the 1975 Bohan and Peter criteria for the diagnosis of dermatomyositis and polymyositis, but Dr. Aggarwal noted these criteria were developed years before the discovery of numerous myositis-associated autoantibodies that have greatly enhanced our understanding of these diseases.1,2 Given this and several other limitations of the Bohan and Peter criteria, the ACR and the European Alliance of Associations for Rheumatology (EULAR) worked together to publish classification criteria for adult and juvenile IIM in 2017.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Sixteen variables were weighted and included in the final classification criteria, and a web-based calculator was developed to provide a score that represents the probability of a specific patient having an IIM. This setup allows researchers using the EULAR/ACR classification criteria to have flexibility in tailoring the inclusion criteria in a study to a certain level of sensitivity or specificity depending on the type of study considered.

In studying the performance of these criteria in a large, monocentric cohort of patients with IIM, Barsotti et al. evaluated 439 consecutive patients with a diagnosis of IIM at the Karolinska University Hospital, Sweden.4 The authors found the EULAR/ACR criteria had a higher sensitivity (87.7%) than the Bohan and Peter criteria (80.4%) and that the EULAR/ACR criteria demonstrated a high specificity (>98%) for the major IIM subgroups polymyositis, dermatomyositis and inclusion body myositis. Given this information, Dr. Aggarwal explained that these new classification criteria represent a great advancement in the field of myositis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In discussing the epidemiology of IIM, Dr. Aggarwal noted these diseases are rare, with an incidence of about eight per one million patients. Aside from juvenile dermatomyositis, the typical age of onset of IIM is between the ages of 30 and 60, with specific forms of disease, such as inclusion body myositis (IBM), occurring most specifically in patients 50 and older. On that note, IBM is more common in male patients while other forms of IIM are seen more often in women than men in a ratio of about 2:1. Finally, although all ethnic groups can be affected by IIM, these diseases are most common in Black patients.

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Systemic Inflammatory Syndromes Tagged With: ACR Convergence 2021, myositis

You Might Also Like:
  • New Approaches to Inflammatory Myopathy
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed
  • Myositis Management: Clinical Trials Provide New Insights into Treatment Options

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.